TauroLock™-Hep500 is approved to be instilled into catheter-based devices for hemodialysis in order to maintain patency of the vascular access device. Additionally, by creating a hostile environment to bacterial and fungal growth, the risk of catheter-related bloodstream infections (CRBSI) is reduced.
Ingredients / Specification:
TauroLock™-Hep500 contains anticoagulant and antimicrobial substances. Active ingredients in TauroLock™-Hep500 are taurolidine, citrate (4%) and heparin (500 IU/mL). The product is a sterile filter processed and supplied as a clear, sterile, non-pyrogenic solution. TauroLock™-Hep500 is to be used with a catheter-based vascular access device. It is to be instilled into the device lumen between treatments (dialysis).
After treatment, the system is thoroughly flushed with saline (min. 10 mL). Then, TauroLock™-Hep500 is instilled into the access system by exactly respecting the filling volume. TauroLock™-Hep500 remains in the system until the next treatment. The solution must be aspirated before initiating the next treatment. Flush the device with 10 mL of saline.
TauroLock™-Hep500 is contraindicated for patients with a known allergy to taurolidine, citrate or heparin, and for patients currently taking medication with known adverse interaction to taurolidine, citrate, or heparin. TauroLock™- Hep500 is also contraindicated for patients with heparin-induced thrombocytopenia or increased bleeding risk.
TauroLock™-Hep500 must be stored at 15 – 30 °C. Do not freeze. It must be neither transported nor stored at freezing conditions. Ampoules are for single-dose only, vials are multi-dose and must be used within 48 hours after the first puncture.
This information does not replace the instructions for use.
Description:TauroLock™-Hep500 catheter lock solution5 ml ampoule (single-dose)
Packaging: 10 x 5 ml
Description: TauroLock™-Hep500 catheter lock solution 10 ml vial (multi-dose)
Packaging: 100 x 10 ml
Pharma Solution is the marketing agent and Distributor for the listed products for the Gulf and MENA region. The products are either registered and approved by the respective local health authority or contracted by the MAH to supply to the end users on a named patient basis. Some products such as Orphan drugs, rare diseases medicines are imported based on special import permits and as per need of the Hospitals in compliance with full documentation.